ASH News Daily 2016 - Issue 1 - A-16


ASH News Daily

Page A-16

Saturday, December 3, 2016

®

M Y E L O P R O L I F E R AT I V E N E O P L A S M S

So, You Don't Know JAK about MPNs?
By Naveen Pemmaraju, MD

T

his year's education session
on myeloproliferative neoplasms (MPNs) will feature
a diverse range of topics, including Dr. Francesco Passamonti discussing the latest updates from
the World Health Organization's
(WHO) reclassification of MPNs.
This is a must-attend session as it
will cover the 2016 classification system that called for practice-changing definitions for some MPNs. For

example, a dramatic lowering of the
hematocrit level in the diagnosis
of polycythemia vera (PV) was put
forth, as well as bumping systemic
mastocytosis into its own unique
category outside of the MPNs due
to its unique biology and clinical
course. Dr. Jamile Shammo will
then discuss the ins and outs of the
constantly shifting mutational landscape of MPNs, which has become
one of the most challenging aspects
of our practice (how and when to
incorporate molecular findings into

prognosis and treatment decisions).
Finally, Dr. Vikas Gupta will lecture
on the application of hematopoietic
cell transplantation for patients with
myelofibrosis, an actively evolving
field with mounting data, and a hot
topic for sure in light of the recent
Center for Medicare Services ruling.
Overall, MPN experts are optimistic about the future for our patients. I recently interviewed two
MPN thought leaders to get their
take on the field: Dr. Ruben Mesa,
who, as the panel chair for the Na-

We're cracking the cancer code.
We're pursuing breakthroughs every day to help put an end to cancer. Exploring every
idea, continually refining our approach, and collaborating with innovators across the
globe to explore cancer genomes as never before. Identifying cancer mutations and
mechanisms, like PD-1 interactions and EGFR, discoveries that help all of us develop
more targeted therapies. Together, we can find solutions to the toughest problems,
because the more answers we find, the more lives we save.

Learn more at
DiscoverCareBelieve.org/code
or visit Booth # 2915.
© 2016 Dana-Farber Cancer Institute

tional Comprehensive Cancer Network, recently oversaw the publication of the Network's first-ever
guidelines for MPNs, and Dr. John
Mascarenhas, who will present the
highly anticipated results of the
PERSIST-2 trial during Monday's
Late-Breaking Abstract Session.
Both highlighted two major areas of
focus for the coming year: interferon
therapy and novel JAK inhibitors,
both as single agents and in combination with other compounds.
What is old is new again, and
the resurgence in interest in an
older therapy, interferon, has made
a splash at the annual meeting this
year. The MPN field eagerly awaits
the results of two key phase III
studies being presented here in San
Diego: ropeginterferon α-2b versus hydroxyurea for patients with
higher risk PV (the PROUD-PV
study, abstract #475), and the MPD
Research Consortium global study
of pegylated interferon versus hydroxyurea in patients with high risk
PV and essential thrombocytopenia
(ET; MPD-RC 112, abstract #479).
"The data from these studies will
be important and impactful as we
evaluate how long-acting interferon
use in PV is viewed in the future,"
explained Dr. Mesa. "Currently it
has been largely used in academic
centers or in patients with more refractory disease, particularly in the
United States. Both the data and
the nuances from these studies will
be important in terms of seeing the
effect on front-line treatment of patients with PV in the near future."
Dr. Mascarenhas adds that the
trials will be critical in determining
the optimal frontline therapy for
high-risk ET and PV, stressing that
hematologists must pay close attention to the differences in tolerability
and efficacy of these very different
agents. "Unfortunately, as we walk
away from this meeting, we will
also have to question whether the
achievement of a hematologic CR
or PR in fact affords a patient an
improved outcome with respect to
reduction in risk of thrombosis, progression to myelofibrosis or acute
myeloid leukemia, and ultimately,
overall survival," he said. "Further
attention to molecular responses is
also important but remains not entirely clear as to the clinical impact."
Updated information will be
made available for analysis, debate,
and discussion regarding two new
JAK inhibitors. First, long-term results from the phase 1/2 trial of
momelotinib is of interest (#1123),
in light of the recent completion
»» MPNs Page A-23



Table of Contents for the Digital Edition of ASH News Daily 2016 - Issue 1

Contents
ASH News Daily 2016 - Issue 1 - A-1
ASH News Daily 2016 - Issue 1 - A-2
ASH News Daily 2016 - Issue 1 - A-3
ASH News Daily 2016 - Issue 1 - A-4
ASH News Daily 2016 - Issue 1 - A-5
ASH News Daily 2016 - Issue 1 - A-6
ASH News Daily 2016 - Issue 1 - A-7
ASH News Daily 2016 - Issue 1 - A-8
ASH News Daily 2016 - Issue 1 - A-9
ASH News Daily 2016 - Issue 1 - A-10
ASH News Daily 2016 - Issue 1 - A-11
ASH News Daily 2016 - Issue 1 - A-12
ASH News Daily 2016 - Issue 1 - A-13
ASH News Daily 2016 - Issue 1 - A-14
ASH News Daily 2016 - Issue 1 - A-15
ASH News Daily 2016 - Issue 1 - A-16
ASH News Daily 2016 - Issue 1 - A-17
ASH News Daily 2016 - Issue 1 - A-18
ASH News Daily 2016 - Issue 1 - A-19
ASH News Daily 2016 - Issue 1 - A-20
ASH News Daily 2016 - Issue 1 - A-21
ASH News Daily 2016 - Issue 1 - A-22
ASH News Daily 2016 - Issue 1 - A-23
ASH News Daily 2016 - Issue 1 - A-24
ASH News Daily 2016 - Issue 1 - A-25
ASH News Daily 2016 - Issue 1 - A-26
ASH News Daily 2016 - Issue 1 - Contents
ASH News Daily 2016 - Issue 1 - B-2
ASH News Daily 2016 - Issue 1 - B-3
ASH News Daily 2016 - Issue 1 - B-4
ASH News Daily 2016 - Issue 1 - B-5
ASH News Daily 2016 - Issue 1 - B-6
ASH News Daily 2016 - Issue 1 - B-7
ASH News Daily 2016 - Issue 1 - B-8
ASH News Daily 2016 - Issue 1 - B-9
ASH News Daily 2016 - Issue 1 - B-10
ASH News Daily 2016 - Issue 1 - B-11
ASH News Daily 2016 - Issue 1 - B-12
ASH News Daily 2016 - Issue 1 - B-13
ASH News Daily 2016 - Issue 1 - B-14
ASH News Daily 2016 - Issue 1 - B-15
ASH News Daily 2016 - Issue 1 - B-16
ASH News Daily 2016 - Issue 1 - B-17
ASH News Daily 2016 - Issue 1 - B-18
ASH News Daily 2016 - Issue 1 - B-19
ASH News Daily 2016 - Issue 1 - B-20
ASH News Daily 2016 - Issue 1 - B-21
ASH News Daily 2016 - Issue 1 - B-22
ASH News Daily 2016 - Issue 1 - B-23
ASH News Daily 2016 - Issue 1 - B-24
ASH News Daily 2016 - Issue 1 - B-25
ASH News Daily 2016 - Issue 1 - B-26
ASH News Daily 2016 - Issue 1 - B-27
ASH News Daily 2016 - Issue 1 - B-28
ASH News Daily 2016 - Issue 1 - B-29
ASH News Daily 2016 - Issue 1 - B-30
ASH News Daily 2016 - Issue 1 - B-31
ASH News Daily 2016 - Issue 1 - B-32
ASH News Daily 2016 - Issue 1 - B-33
ASH News Daily 2016 - Issue 1 - B-34
ASH News Daily 2016 - Issue 1 - B-35
ASH News Daily 2016 - Issue 1 - B-36
ASH News Daily 2016 - Issue 1 - B-37
ASH News Daily 2016 - Issue 1 - B-38
ASH News Daily 2016 - Issue 1 - B-39
ASH News Daily 2016 - Issue 1 - B-40
ASH News Daily 2016 - Issue 1 - B-41
ASH News Daily 2016 - Issue 1 - B-42
ASH News Daily 2016 - Issue 1 - B-43
ASH News Daily 2016 - Issue 1 - B-44
ASH News Daily 2016 - Issue 1 - B-45
ASH News Daily 2016 - Issue 1 - B-46
ASH News Daily 2016 - Issue 1 - B-47
ASH News Daily 2016 - Issue 1 - B-48
ASH News Daily 2016 - Issue 1 - C-1
ASH News Daily 2016 - Issue 1 - C-2
ASH News Daily 2016 - Issue 1 - C-3
ASH News Daily 2016 - Issue 1 - C-4
ASH News Daily 2016 - Issue 1 - C-5
ASH News Daily 2016 - Issue 1 - C-6
ASH News Daily 2016 - Issue 1 - C-7
ASH News Daily 2016 - Issue 1 - C-8
ASH News Daily 2016 - Issue 1 - C-9
ASH News Daily 2016 - Issue 1 - C-10
ASH News Daily 2016 - Issue 1 - C-11
ASH News Daily 2016 - Issue 1 - C-12
ASH News Daily 2016 - Issue 1 - C-13
ASH News Daily 2016 - Issue 1 - C-14
ASH News Daily 2016 - Issue 1 - C-15
ASH News Daily 2016 - Issue 1 - C-16
ASH News Daily 2016 - Issue 1 - C-17
ASH News Daily 2016 - Issue 1 - C-18
ASH News Daily 2016 - Issue 1 - C-19
ASH News Daily 2016 - Issue 1 - C-20
ASH News Daily 2016 - Issue 1 - C-21
ASH News Daily 2016 - Issue 1 - C-22
ASH News Daily 2016 - Issue 1 - C-23
ASH News Daily 2016 - Issue 1 - C-24
ASH News Daily 2016 - Issue 1 - C-25
ASH News Daily 2016 - Issue 1 - C-26
http://www.nxtbookMEDIA.com